Immunovant (IMVT)
Developing imeroprubart across six IgG-driven autoimmune diseases.
Something off on this page? Send us feedback.
Develops imeroprubart, a subcutaneous anti-FcRn antibody in clinical studies across six IgG-driven autoimmune diseases. With no approved products or revenue, the business depends on clinical and regulatory progress, HanAll-licensed rights, third-party clinical and manufacturing partners, and Roivant's controlling ownership.
Develops imeroprubart (IMVT-1402), a subcutaneous antibody that blocks FcRn to reduce pathogenic IgG in autoimmune disease. The clinical program spans Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and cutaneous lupus erythematosus.
Runs six studies with the intended commercial formulation and autoinjector. Batoclimab was discontinued after thyroid eye disease studies missed their primary endpoint, concentrating resources and prior trial experience on imeroprubart.
Operates as a single research, development, and manufacturing segment with no approved products or revenue. Progress depends on clinical results and regulatory approval; HanAll licenses core rights across the Americas, Europe, the Middle East, and North Africa, outside partners run trials and manufacturing, and Roivant remains the majority owner.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 21, 2026 | H.C. Wainwright | Target | Target: $51 | Target: $40 |
| Jan 6, 2026 | Wolfe Research | Upgrade | Target: — | Target: $50 |
| Dec 18, 2025 | Guggenheim | Target | Target: $48 | Target: $41 |
| Oct 14, 2025 | Truist Financial | Target | Target: — | Target: $16 |
| Apr 22, 2025 | UBS | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $797.8M · Total debt $0 · Total assets $852.5M · Shareholders' equity $735.4M
- Revenue
- $7.1M
- Operating income
- −$153.2M
- Net income
- −$153.2M
No dividends on record.
| Institutions | 53.77% | 111.07M shares | |
|---|---|---|---|
| 240 holders · as of Jun 30, 2026 | |||
| Insiders | 1.42% | 2.93M shares | |
| 15 holders · as of Aug 28, 2026 | |||
| Strategic holders | 54.87% | 113.33M shares | |
| 1 holder · as of Dec 12, 2025 | |||
| Adds to | 110.06% | ||
206.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 110.06%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Roivant Sciences Ltd.Strategicdirector, 10 percent owner | 54.87% | 113.33M | filed Dec 12, 2025 |
FMR LLCInstitution | 7.84% | 16.19M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 4.52% | 9.34M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 3.48% | 7.18M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 2.81% | 5.81M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Atul Pande | director | −1,500 | $43.27 |
| Aug 20, 2026 | Melanie Gloria | officer: Chief Operating Officer | −3,056 | $44.16 |
| Jul 23, 2026 | Jay S. Stout | officer: Chief Technology Officer | −2,857 | $38.69 |
| Jul 23, 2026 | Tiago Girao | officer: Chief Financial Officer | −6,798 | $38.69 |
| Jul 24, 2026 | Atul Pande | director | −1,500 | $39.80 |
- argenx (ADR)
Leading FcRn franchise in gMG, CIDP, Sjogren's, and Graves'
- Johnson & Johnson
Large-pharma FcRn platform spanning gMG and Sjogren's
- Viridian Therapeutics
Next-generation FcRn and thyroid-autoimmunity programs
- Novartis (ADR)
Phase III Sjogren's B-cell program
- Vor Biopharma
Telitacicept rights in gMG, Sjogren's, SLE, and RA
- Amgen
Sjogren's and thyroid-autoimmunity substitute programs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immunovant | $37.50 | +0.86% | $7.67B | — | — | 1,081.6 | — |
| argenx (ADR) | $973.75 | −1.46% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Johnson & Johnson | $268.51 | −0.36% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Viridian Therapeutics | $21.95 | +1.73% | $2.44B | — | — | 34.4 | +278.7% |
| Novartis (ADR) | $141.21 | +0.16% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Vor Biopharma | $22.69 | +3.63% | $1.19B | — | — | — | — |
| Amgen | $407.42 | +3.63% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Median | 27.8 | 17.4 | 6.6 | +9.7% |